JMP Securities Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $47
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has maintained a Market Outperform rating on Sagimet Biosciences (NASDAQ:SGMT) and increased the price target from $31 to $47.
January 22, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst has reaffirmed a Market Outperform rating on Sagimet Biosciences and raised the price target to $47, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically suggests a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100